Dirk Pleimes
Chief Executive Officer PentixaPharm GmbH
Dr. Dirk Pleimes is Group CEO & CMO of Pentixapharm Holding AG, a clinical-stage radiopharmaceutical company focused on theranostic innovation. He has a background in strategic, scientific and medical leadership, having co-founded and led biotech and pharma ventures and held research & clinical development roles across disciplines. Since April 2025, he formally assumed the CEO role while continuing his responsibilities as CMO.
Seminars
Thinking about entering radiopharma – or wish you’d known more before you did? Join seasoned leaders from R&D, CMC, clinical, and commercial as they share hard-won lessons, practical pitfalls, and insider insights across the entire development journey, and bring your questions to those who’ve navigated it firsthand.
- R&D and Preclinical: novel target choices, targeting molecules, linkers, chelators, preclinical dosimetry and more
- CMC and Regulatory: isotope properties, differences in supply chain, logistics networks, CMC innovations, regulatory considerations and more
- Clinical Development: clinical trial design, working with sites, working with clinical stakeholders, patient centric approaches and more
- Characterizing early hematologic effects and dose-limiting toxicities using Phase 0 microdosing studies
- Dissecting mechanisms of bystander irradiation contributing to bone marrow exposure and cytopenias
- Informing dose escalation and safety margins for subsequent first-in-human and Phase 1 trials
